accountNEW YORK (Reuters) - The head of infectious diseases at Merck & Co said the company's future all-oral treatments for hepatitis C and its experimental drug for infections with clostridium difficile
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Merck aims at hepatitis, c. difficile drugs | Reuters
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account